Stockscreener 앱 받기
1.47
2.08%
0.03
전일 마감가:
$1.44
열려 있는:
$1.44
하루 거래량:
17,280
Relative Volume:
0.01
시가총액:
$7.75M
수익:
$32.96M
순이익/손실:
$-4.23M
주가수익비율:
-0.00946
EPS:
-155.3294
순현금흐름:
$-14.00M
1주 성능:
-1.34%
1개월 성능:
+2.80%
6개월 성능:
-51.00%
1년 성능:
-81.76%
1일 변동 폭
$1.43
$1.49
1주일 범위
$1.39
$1.58
52주 변동 폭
$1.1693
$8.026
Sunshine Biopharma Inc Stock (SBFM) Company Profile
명칭
Sunshine Biopharma Inc
전화
954-515-0810
주소
333 LAS OLAS WAY, FORT LAUDERDALE
SBFM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SBFM
Sunshine Biopharma Inc
|
1.47 | 7.75M | 32.96M | -4.23M | -14.00M | -155.33 |
|
RGC
Regencell Bioscience Holdings Ltd
|
15.83 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
158.31 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.36 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.39 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.66 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Sunshine Biopharma Inc 주식(SBFM)의 최신 뉴스
Sunshine Biopharma (NASDAQ:SBFMW) Trading Down 3.8% – Here’s Why - Defense World
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’ - MSN
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic P - GuruFocus
Sunshine Biopharma launches generic anticonvulsant drug in Canada By Investing.com - Investing.com South Africa
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’ By Stocktwits - Investing.com India
Sunshine Biopharma (SBFM) Expands Portfolio with New Gabapentin Launch | SBFM Stock News - GuruFocus
Sunshine Biopharma launches generic anticonvulsant drug in Canada - Investing.com
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market - Yahoo Finance
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees 'Huge Potential' - MENAFN.com
Sunshine Biopharma (NASDAQ:SBFMW) Trading 17.8% Higher – Here’s Why - Defense World
Sunshine Biopharma Sees 18% Revenue Growth in Q1 2025 - TipRanks
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues - GuruFocus
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year - ACCESS Newswire
Sunshine Biopharma Reports Double-Digit Growth: Q1 Revenue Jumps 18% as Pipeline Expands with 6 New Drugs - Stock Titan
Sunshine Biopharma (NASDAQ:SBFM) Stock Price Up 8% – Here’s Why - Defense World
Sunshine Biopharma launches generic antipsychotic drug - Investing.com Australia
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia - GuruFocus
Sunshine Biopharma (SBFM) Unveils Generic Antipsychotic Drug in Canada | SBFM Stock News - GuruFocus
Sunshine Biopharma launches generic antipsychotic drug By Investing.com - Investing.com Canada
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market - ACCESS Newswire
Sunshine Biopharma Challenges $1.2B Antipsychotic Market With New Generic Latuda Alternative - Stock Titan
Certain Warrants of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2025. - marketscreener.com
Sunshine Biopharma Inc’s Market Journey: Closing Weak at 1.84, Down -18.22 - DWinneX
Sunshine Biopharma (NASDAQ:SBFMW) Stock Price Down 4.5% – Here’s Why - Defense World
There is no doubt that Sunshine Biopharma Inc (SBFM) ticks all the boxes. - Sete News
Sunshine Becomes Latest To Compete On Everolimus In Canada - insights.citeline.com
Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug - Asianet Newsable
Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug By Stocktwits - Investing.com India
SBFM Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Sunshine Biopharma enters Canadian generic drug market with Everolimus By Investing.com - Investing.com South Africa
Press Release Distribution & PR Platform - ACCESS Newswire
SBFM’s valuation metrics: A comprehensive analysis - uspostnews.com
Sunshine Biopharma (SBFM) Finalizes $2.46 Million Stock Offering - GuruFocus
Sunshine Biopharma Unit Rolls Out Afinitor Alternative Everolimus in Canadian Market - marketscreener.com
Sunshine Biopharma enters Canadian generic drug market with Everolimus - Investing.com
Sunshine Biopharma (SBFM) Launches Generic Everolimus in Canada | SBFM Stock News - GuruFocus
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion | SBFM Stock News - GuruFocus
Major Cancer Treatment Everolimus Enters Canadian Market: Multiple Cancer Types Targeted in $2.5B Opportunity - Stock Titan
Sunshine Biopharma (SBFM) Launches Generic Everolimus in Canada - GuruFocus
Sunshine Biopharma stock hits 52-week low at $1.24 - Investing.com Australia
Sunshine Biopharma stock hits 52-week low at $1.24 By Investing.com - Investing.com India
Sunshine Biopharma (NASDAQ:SBFMW) Trading Down 10.9% – Here’s Why - Defense World
Sunshine Biopharma stock hits 52-week low at $1.85 amid steep decline By Investing.com - Investing.com South Africa
Sunshine Biopharma Closes $2.46 Million Direct Offering - TipRanks
Sunshine Biopharma Secures $2.46 Million in Direct Offering - TipRanks
Sunshine Biopharma Closes $2.5 Million Direct Offering - MarketScreener
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering - ACCESS Newswire
Sunshine Biopharma Inc (SBFM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
0.64%
자본화:
|
볼륨(24시간):